Christina Leicht's research while affiliated with University Hospital Regensburg and other places

Publications (4)

Article
Full-text available
The role of adjuvant chemotherapy in patients with locally advanced bladder cancer still remains to be defined. We hypothesized that assessing the gene expression of the chemotherapy response modifiers multidrug resistance gene 1 (MDR1) and excision repair cross-complementing 1 (ERCC1) may help identify the group of patients benefiting from cisplat...
Article
Full-text available
PURPOSE: The role of adjuvant chemotherapy in patients with locally advanced bladder cancer still remains to be defined. We hypothesized that assessing the gene expression of the chemotherapy response modifiers multidrug resistance gene 1 (MDR1) and excision repair crosscomplementing 1 (ERCC1) may help identify the group of patients benefiting from...
Article
e22081 Background: The human MDR1 gene encodes an integral membrane protein, P glycoprotein (Pgp), whose function is the energy dependent export of substances from the inside of cells, and from membranes, to the outside. MDR1 mRNA levels have been shown to influence metabolism of cancer drugs. We tested whether MDR1 gene expression is associated wi...
Article
5026 Background: The human MDR1 gene encodes an integral membrane protein, P glycoprotein (Pgp), whose function is the energy dependent export of substances from the inside of cells, and from membranes, to the outside. MDR1 mRNA levels have been shown to influence metabolism of cancer drugs. We tested whether MDR1 gene expression is associated with...

Citations

... In urothelial carcinoma, low ERCC1 levels by either mRNA quantification or IHC have also been associated with improved response to cisplatin in the perioperative and metastatic settings [23][24][25][26][27][28][29][30][31][32][33][34] . In 2007, Bellmunt et al. [34] reported a retrospective analysis of 57 mUC patients treated with GC-based regimens; low levels of ERCC1 mRNA expression correlated with improved OS (25.4 months vs. 15.4 months, P = 0.03). ...
... Although for practical reasons, studies have often concentrated on the assessment of one genetic marker, it seems likely that multiple markers can influence chemotherapy efficacy. While high MDR1 expression determined by RT-PCR was associated with a shorter survival in patients with locally advanced bladder cancer treated with adjuvant cisplatin/methotrexate [29], Takata et al. [30] used microarray analysis to identify a set of genes related to response to neoadjuvant chemotherapy. In another study of bladder cancer patients treated with neoadjuvant M-VAC, using multivariate gene expression models based on biomarkers of in vitro drug sensitivity, the 3-year overall survival for patients with favorable gene expression scores was 81% versus 33% for those with less favorable scores [31]. ...
... For example, substantial attention has been given to ATP-binding cassette (ABC) transporters, such as p-glycoprotein (also known as MDR1), which is commonly overexpressed in cancers [9, 10]. High p-glycoprotein expression was shown to correlate with a poor prognosis in bladder cancer patients after cisplatin-based adjuvant chemotherapy [11]. Interestingly, recent studies have shown that repressing p-glycoprotein via gene-silencing strategies is able to enhance the effects of cisplatin in hepatocellular carcinoma [12]. ...